Ferdinand Kiemeneij, M.D., explains the history of the transradial access during an interview with DAIC at TCT 2017.
Radial access hemostasis with an Advanced Vascular RadAR Model 4160 device.
Ferdinand Kiemeneij, M.D., explains the history of the transradial access technique with DAIC editor Dave Fornell at TCT 2017.

Interventional cardiology has witnessed a rapid and constant evolution in both techniques and device technology since its start in the 1980s. One of the chief motivators for this has been operators continually looking to build a better mousetrap that overcomes new problems encountered to improve patient outcomes. A key technique that has had a lasting impact on interventional cardiology was the development of transradial vascular access for percutaneous coronary intervention (PCI) a quarter century ago.

When someone goes into cardiac arrest and first responders cannot shock their heart back into rhythm, there is virtually no chance of survival. However, a new protocol being tested at The Ohio State University Wexner Medical Center is already saving lives – increasing survival rates from zero to about 40 percent.

February 22, 2018 — AtriCure Inc. announced that it has launched the AtriClip FLEX•V Left Atrial Appendage (LAA) Exclusion System in the United States. The new system is the first device of the AtriClip family to offer a clip deployment trigger release. The device also offers an open-ended AtriClip design combined with a tip-first closure mechanism to enable easier navigation and placement in cardiac surgeries.

South Africa Heart Congress (SA Heart)

Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional financing – bringing total equity and debt financing in the current round to $41 million. The additional financing exceeds previous commitments for this round and includes returning equity and debt investors – including PTV Healthcare Capital, Canepa Healthcare, and affiliates of Luther King Capital Management.

The U.S. Food and Drug Administration (FDA) issued the final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Devices.” The rule updates the FDA’s standards for accepting clinical data from clinical investigations conducted both inside and outside the United States to help ensure the protection of human participants, and to help ensure the quality and integrity of data obtained from these clinical investigations.

Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device, according to the company, to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.

Society of Cardiovascular Computed Tomography (SCCT)

American Society of Echocardiography (ASE)

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now